Managers
Polaris Private Equity (Polaris) has successfully completed a first closing of its fourth private equity fund – Polaris Private Equity IV – at DKK2.2 billion (EUR300 million).
The fund, which is believed to have a target size of DKK3.0 billion, became operational as of 1 January 2015, simultaneous with the expiry of the investment period of the predecessor fund, Polaris Private Equity III.
Jan Johan Kühl, Managing Partner at Polaris, says: “We are pleased to have held a quick and strong first close for our latest fund. We deliver strong returns to our investors, founded upon our philosophy of investing
With As the first AIFMD reporting deadline for many managers of Alternative Investment Funds (AIFs) looming large on 30 January 2015, firms may turn to outsourcing to meet their obligations.
A survey conducted by the Financial Services team of Moore Stephens highlighted that only half of AIFMs are fully aware of the Annex IV reporting requirements applicable to them and the timetable for submission, with a further 42% being somewhat aware but unsure of the information required. Almost 35% of AIFMs surveyed stated that they were not prepared for the actual reporting process.
Moore Stephens believes that the lack
Private equity firm Arlington Capital Partners has acquired United Flexible Group, a specialist in flexible engineered solutions for the transfer of fluids and gases in extreme environments.
The company is a proactive partner to blue chip OEMs operating in several attractive end-markets including aerospace/defence, satellite, power generation, general industrial, oil/gas, cooling and transportation.
United has over 330 employees with manufacturing operations in Romeoville, Illinois; Houston, Texas; Merthyr Tydfil, Wales, UK; Rotterdam, The Netherlands; and Knivsta, Sweden, and operates through several subsidiary entities, including US Hose Corporation, AmniTec Ltd, AmniTec BV and Habia Teknofluor. The Company’s critical flexible engineered solutions reduce
Prism Medical, a manufacturer and provider of specialist mobility and handling equipment, has completed the acquisition of The Mobility Equipment Company (TMEC) for an undisclosed sum.
The deal, which was transacted with support from leading mid-market private equity provider LDC, who invested in the GBP30million acquisition of Prism Medical in April 2014, forms part of the business’ on-going acquisitive growth strategy.
Prism Medical is the market leader in the provision of moving & handling solutions that enable the mobility disadvantaged to live at home in a safe and dignified manner, thereby helping to improve their quality of life. In addition
Over the past year, a total of 7,474 venture capital financings were announced globally with an aggregate value of USD86.6bn, according to Preqin.
This represents an 11% fall in the number of financings taking place compared to 2013, but a 58% rise in the aggregate value of deals compared to the previous year. Companies located in Asia and other regions outside North America and Europe have been the primary benefactors of this increase in financing, with the amount of capital invested across these regions up 160% in 2014 compared to deals done in 2013.
Although North America was again the
Private equity house Key Capital Partners (KCP) has exited its investment in Nurse Plus to a secondary MBO funded by Sovereign Capital (Sovereign) and led by Nurse Plus CEO Heath Blake and MD Pamela Bruce.
The transaction gives KCP an attractive return on its original investment and represents the firm's third successful exit in 2014 following on from its sales of TSC Foods and Neville Johnson earlier in the year.
Established in 2005, Nurse Plus is a healthcare services provider, specialising in domiciliary care services and providing flexible staffing solutions for care homes and hospitals.
Under KCP ownership
One of the inherent risks to investing in hedge funds is the inherent volatility of performance. A top fund today might be the worst tomorrow. In Preqin’s latest November Hedge Fund Spotlight report, which looks at this year’s top 100 performing hedge funds, only three funds feature on the list from 2013.
To qualify, only those funds with USD100m or more in AuM were considered. The sample period was October 2013 through September 2014.
What is clear from the list is that the top performing funds over the past 12 months are more volatile. Whereas year-on-year only three funds made
KKR has sold its remaining stake in Alliance Boots to Walgreens Boots Alliance following the exercise by Walgreens of the call option to acquire the remaining 55% of Alliance Boots as the second step of the overall transaction.
In August 2012, Walgreens acquired 45% of Alliance Boots in the first step of the overall transaction.
Dominic Murphy, Member, Head of KKR operations in the United Kingdom says: “The investment in Alliance Boots adds to our track record of partnering with European entrepreneurs to build global companies and industry leaders. Since Alliance Boots was taken private in 2007, a strong investment
Private equity investment firm Pamplona Capital Management is to acquire Charter NEX Films, subject to customary conditions, including expiration of the waiting period under the Hart-Scott-Rodino Act.
The transaction is expected to be completed during the first quarter of 2015.
Charter NEX Films is a leading independent producer of high performance polyethylene films. It holds a leading position within flexible food and consumer product packaging, and strong, growing positions in medical, pharmaceutical and industrial surface protection segments. The Company is benefiting from very strong growth in its key product categories, such as stand-up pouches, and is a valued partner for
Dynavax Technologies Corporation has entered into a credit facility with Hercules Technology Growth Capital for up to USD40 million of total funding.
Dynavax drew the first tranche of USD10 million on closing and has access to an additional USD30 million in 2015, at Dynavax's option, if it achieves certain milestones relating to the ongoing Phase 3 study of HEPLISAV-B (HBV-23).
"This credit facility provides us access to up to USD40 million of non-dilutive funding that can be used to support development and pre-commercialization activities for HEPLISAV-B, clinical trials of our cancer immunotherapeutic product candidate, SD-101, and advancement of our research
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
